FDA Issues Guidance Doc on Reclassifying NAT TB Tests as 'Moderate Risk' | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has issued a draft guidance suggesting the reclassification of nucleic acid-based tests for detecting tuberculosis from Class III (high risk) to Class II (moderate risk).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.